At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
CP-690,550 + methotrexate +1 moredrug
Likely dose
CP-690,550 + methotrexate 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Pharmacodynamics Of CP-690,550, Administered Orally Twice Daily (BID) For 4 Weeks, In Subjects With Active Rheumatoid Arthritis
In Brief
A Phase 2 clinical trial evaluating CP-690,550 + methotrexate and Placebo + Methotrexate for Rheumatoid Arthritis. Completed, enrolled 29 participants across 15 sites.
Detailed Summary
To explore the effect of CP-690,550 on blood and synovial markers in subjects with rheumatoid arthritis. To evaluate the safety, tolerability and efficacy of CP-690,550.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartNov 2009
Primary CompletionJul 2011
TodayJul 2026
First PostedSep 14, 2009
Enrollment StartNov 1, 2009
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.8 years ago
Interventions
CP-690,550 + methotrexatedrug
CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
Placebo + Methotrexatedrug
Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week